Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Oct 31;2014(10):CD008046.
doi: 10.1002/14651858.CD008046.pub4.

Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology

Mohamed A F M Youssef  1 , Fulco Van der Veen, Hesham G Al-Inany, Monique H Mochtar, Georg Griesinger, Mohamed Nagi Mohesen, Ismail Aboulfoutouh, Madelon van Wely
Affiliations
Meta-Analysis

Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology

Mohamed A F M Youssef et al. Cochrane Database Syst Rev. .

Abstract

Background: Human chorionic gonadotropin (HCG) is routinely used for final oocyte maturation triggering in in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) cycles, but the use of HCG for this purpose may have drawbacks. Gonadotropin-releasing hormone (GnRH) agonists present an alternative to HCG in controlled ovarian hyperstimulation (COH) treatment regimens in which the cycle has been down-regulated with a GnRH antagonist. This is an update of a review first published in 2010.

Objectives: To evaluate the effectiveness and safety of GnRH agonists in comparison with HCG for triggering final oocyte maturation in IVF and ICSI for women undergoing COH in a GnRH antagonist protocol.

Search methods: We searched databases including the Menstrual Disorders and Subfertility Group (MDSG) Specialised Register of Controlled Trials, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO, the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and trial registers for published and unpublished articles (in any language) on randomised controlled trials (RCTs) of gonadotropin-releasing hormone agonists versus HCG for oocyte triggering in GnRH antagonist IVF/ICSI treatment cycles. The search is current to 8 September 2014.

Selection criteria: RCTs that compared the clinical outcomes of GnRH agonist triggers versus HCG for final oocyte maturation triggering in women undergoing GnRH antagonist IVF/ICSI treatment cycles were included.

Data collection and analysis: Two or more review authors independently selected studies, extracted data and assessed study risk of bias. Treatment effects were summarised using a fixed-effect model, and subgroup analyses were conducted to explore potential sources of heterogeneity. Treatment effects were expressed as mean differences (MDs) for continuous outcomes and as odds ratios (ORs) for dichotomous outcomes, together with 95% confidence intervals (CIs). Primary outcomes were live birth and rate of ovarian hyperstimulation syndrome (OHSS) per women randomised. Grades of Recommendation, Assessment, Development and Evaluation (GRADE) methods were used to assess the quality of the evidence for each comparison.

Main results: We included 17 RCTs (n = 1847), of which 13 studies assessed fresh autologous cycles and four studies assessed donor-recipient cycles. In fresh autologous cycles, GnRH agonists were associated with a lower live birth rate than was seen with HCG (OR 0.47, 95% CI 0.31 to 0.70; five RCTs, 532 women, I(2) = 56%, moderate-quality evidence). This suggests that for a woman with a 31% chance of achieving live birth with the use of HCG, the chance of a live birth with the use of an GnRH agonist would be between 12% and 24%.In women undergoing fresh autologous cycles, GnRH agonists were associated with a lower incidence of mild, moderate or severe OHSS than was HCG (OR 0.15, 95% CI 0.05 to 0.47; eight RCTs, 989 women, I² = 42%, moderate-quality evidence). This suggests that for a woman with a 5% risk of mild, moderate or severe OHSS with the use of HCG, the risk of OHSS with the use of a GnRH agonist would be between nil and 2%.In women undergoing fresh autologous cycles, GnRH agonists were associated with a lower ongoing pregnancy rate than was seen with HCG (OR 0.70, 95% CI 0.54 to 0.91; 11 studies, 1198 women, I(2) = 59%, low-quality evidence) and a higher early miscarriage rate (OR 1.74, 95% CI 1.10 to 2.75; 11 RCTs, 1198 women, I² = 1%, moderate-quality evidence). However, the effect was dependent on the type of luteal phase support provided (with or without luteinising hormone (LH) activity); the higher rate of pregnancies in the HCG group applied only to the group that received luteal phase support without LH activity (OR 0.36, 95% CI 0.21 to 0.62; I(2) = 73%, five RCTs, 370 women). No evidence was found of a difference between groups in risk of multiple pregnancy (OR 3.00, 95% CI 0.30 to 30.47; two RCTs, 62 women, I(2) = 0%, low-quality evidence).In women with donor-recipient cycles, no evidence suggested a difference between groups in live birth rate (OR 0.92, 95% CI 0.53 to 1.61; one RCT, 212 women) or ongoing pregnancy rate (OR 0.88, 95% CI 0.58 to 1.32; three RCTs, 372 women, I² = 0%). We found evidence of a lower incidence of OHSS in the GnRH agonist group than in the HCG group (OR 0.05, 95% CI 0.01 to 0.28; three RCTs, 374 women, I² = 0%).The main limitation in the quality of the evidence was risk of bias associated with poor reporting of methods in the included studies.

Authors' conclusions: Final oocyte maturation triggering with GnRH agonist instead of HCG in fresh autologous GnRH antagonist IVF/ICSI treatment cycles prevents OHSS to the detriment of the live birth rate. In donor-recipient cycles, use of GnRH agonists instead of HCG resulted in a lower incidence of OHSS, with no evidence of a difference in live birth rate.Evidence suggests that GnRH agonist as a final oocyte maturation trigger in fresh autologous cycles is associated with a lower live birth rate, a lower ongoing pregnancy rate (pregnancy beyond 12 weeks) and a higher rate of early miscarriage (less than 12 weeks). GnRH agonist as an oocyte maturation trigger could be useful for women who choose to avoid fresh transfers (for whatever reason), women who donate oocytes to recipients or women who wish to freeze their eggs for later use in the context of fertility preservation.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
3
3
Methodological risk of bias summary: review authors' judgements about each methodological quality item for each included study.
4
4
GnRH agonist versus HCG for oocyte maturation triggering, outcome: 1.1 Live birth rate per women randomly assigned.
5
5
GnRH agonist versus HCG for oocyte maturation triggering, outcome: 1.2 OHSS incidence per women randomly assigned.
6
6
GnRH agonist versus HCG for oocyte maturation triggering, outcome: 1.3 Ongoing pregnancy rate per women randomly assigned.
7
7
Funnel plot of comparison: 1 GnRH agonist versus HCG for oocyte maturation triggering, outcome: 1.5 Ongoing pregnancy rate per woman randomised.
1.1
1.1. Analysis
Comparison 1 GnRH agonist versus HCG for oocyte maturation triggering, Outcome 1 Live birth rate per woman randomised.
1.2
1.2. Analysis
Comparison 1 GnRH agonist versus HCG for oocyte maturation triggering, Outcome 2 Live birth rate in autologous cycles: luteal phase support approach.
1.3
1.3. Analysis
Comparison 1 GnRH agonist versus HCG for oocyte maturation triggering, Outcome 3 OHSS incidence per woman randomised.
1.4
1.4. Analysis
Comparison 1 GnRH agonist versus HCG for oocyte maturation triggering, Outcome 4 OHSS rate in autologous cycles: luteal support approach.
1.5
1.5. Analysis
Comparison 1 GnRH agonist versus HCG for oocyte maturation triggering, Outcome 5 Ongoing pregnancy rate per woman randomised.
1.6
1.6. Analysis
Comparison 1 GnRH agonist versus HCG for oocyte maturation triggering, Outcome 6 Ongoing pregnancy rate in autologous cycles: luteal phase support approach.
1.7
1.7. Analysis
Comparison 1 GnRH agonist versus HCG for oocyte maturation triggering, Outcome 7 Clinical pregnancy per woman randomised.
1.8
1.8. Analysis
Comparison 1 GnRH agonist versus HCG for oocyte maturation triggering, Outcome 8 Miscarriage rate per woman randomised.
1.9
1.9. Analysis
Comparison 1 GnRH agonist versus HCG for oocyte maturation triggering, Outcome 9 Multiple pregnancy rate per woman randomised.
1.10
1.10. Analysis
Comparison 1 GnRH agonist versus HCG for oocyte maturation triggering, Outcome 10 Subgroup and sensitivity analyses—OHSS incidence in autologous cycles: risk and severity.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Acevedo 2006 {published data only}
    1. Acevedo B, Jose Gomez‐Palomares L, Ricciarelli E, Hernández ER. Triggering ovulation with gonadotropin‐releasing hormone agonists does not compromise embryo implantation rates. Fertility and Sterility 2006;86(6):1682‐7. - PubMed
Babayof 2006 {published data only}
    1. Babayof R, Margalioth J E, Huleihel M, Amash A, Zylber‐Haran E, Gal M, et al. Serum inhibin A, VEGF and TNFa levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Human Reproduction 2006;21(5):1260–5. - PubMed
Beckers 2003 {published data only}
    1. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, et al. Non supplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin‐releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle‐stimulating hormone and GnRH antagonist cotreatment. The Journal of Clinical Endocrinology and Metabolism 2003;88(9):4186–92. [DOI: 10.1210/jc.2002-021953] - DOI - PubMed
Engmann 2008 {published data only}
    1. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin‐releasing hormone (GnRH) agonist to induce oocyte maturation after co‐treatment with GnRH antagonist in high‐risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertility and Sterility 2008;89(1):84‐91. [DOI: ] - PubMed
Fauser 2002 {published data only}
    1. Fauser BC, Jong D, Olivennes F, Warmsby H, Tay CJ, Itskovitz‐Eldor J, Hooren HG. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. The Journal of Clinical Endocrinology and Metabolism 2002;87(2):709‐15. - PubMed
Galindo 2009 {published data only}
    1. Galindo A, Bodri D, Guillén JJ, Colodrón M, Vernaeve V, Coll O. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecology Endocrinolology 2009;25(1):60‐6. - PubMed
Humaidan 2005 {published data only}
    1. Humaidan P, Bredkjær HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, Andersen CY. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Human Reproduction 2005;20(5):1213–20. [DOI: 10.1093/humrep/deh765] - DOI - PubMed
Humaidan 2006 {published data only}
    1. Humaidan P, Bungum M, Andersen CY. Rescue of corpus luteum function with periovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reproductive BioMedicine Online 2006;13(2):173‐8. - PubMed
Humaidan 2010 {published data only}
    1. Humaidan P, Bredkjær HE, Westergaard L, Andersen CY. 1500 IU hCG secures a normal clinical pregnancy outcome in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist. Fertility and Sterility 2010;93(3):847‐54. [DOI: 10.1016/j.fertnstert.2008.12.042] - DOI - PubMed
Humaidan 2013 {published data only}
    1. Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi‐centre studies in IVF patients. Human Reproduction 2013;28(9):2511‐21. - PubMed
Kolibianakis 2005 {published data only}
    1. Kolibianakis EM, Schultze‐Mosgau A, Schroer A, Steirteghem A, Devroey P, Diedrich K, et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Human Reproduction 2005;20(10):2887–92. [DOI: 10.1093/humrep/dei150; PUBMED] - DOI - PubMed
Melo 2009 {published data only}
    1. Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor‐blind study.. Reproductive BioMedicine Online 2009;19(4):486‐92. - PubMed
Ossina 2004 {published data only}
    1. Ossina E, Yavorovskaya K, Kuzmichev L, Kornilov N, Belikov V, Belikova O, et al. Triggering of final oocyte maturation in GnRH antagonist IVFprotocols: triptorelin 0.1 mg versus hCG. A randomized multi centre trial. Abstracts of the 20th Annual Meeting of the ESHRE, Berlin, Germany, 27‐30 June 2004;19(1):i99‐i102.
Papanikolaou 2010 {published data only}
    1. Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, Devroey P, Tournaye H. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin‐releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertility and Sterility 2011;95(3):1174‐7. - PubMed
Peňa 2007 {published data only}
    1. Peña V, Chinea E, Sanabria V, Hernandez J, Palumbo A. Triggering final oocyte maturation with a GnRH agonist in egg donors does not reduce implantation and pregnancy rates and eliminates the risk of OHSS. Abstracts of the 23rd Annual Meeting of the ESHRE,Lyon, France, 1‐4 July 2007;22(1):i123.
Pirard 2006 {published data only}
    1. Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Human Reproduction 2006;21(7):1894‐900. [DOI: 10.1093/humrep/del072] - DOI - PubMed
Segal 1992 {published data only}
    1. Segal S, Casper RF. Gonadotropin‐releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization. Fertility and Sterility 1992; Vol. 57, issue 6:1254‐8. - PubMed

References to studies excluded from this review

Andersen 2006 {published data only}
    1. Andersen CY, Humaidan P, Ejdrup HP, Bungum L, Grøndah ML, Westergaard LG. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. Human Reproduction 2006;21(8):2126–30. - PubMed
Andreyko 2011 {published data only}
    1. Murray AM, Soto‐Albors C. Use of combined oral and vaginal estradiol and IM and vaginal progesterone in luteal phase of antagonist cycles triggered with GnRH agonist results in good clinical pregnancy rates. Fertility and Sterility 2011;45:S25.
Awaad 2012 {published data only}
    1. Awwad JT, Hannoun AB, Khalil A, Younes ZM, Ghazeeri GS. Induction of final follicle maturation with a gonadotropin‐releasing hormone agonist in women at risk of ovarian hyperstimulation syndrome undergoing gonadotropin stimulation and intrauterine insemination: proof‐of‐concept study. Clinical and Experimental Obstetrics and Gynecology 2012;39(4):436‐9. - PubMed
Bankowaski 2004 {published data only}
    1. Bankowski B, Bracero N, King J, Garcia J, Wallach E, Vlahos N. Triggering ovulation with leuprolide acetate is associated with lower pregnancy rates. Abstracts of the 20th Annual Meeting of the ESHRE, Berlin, Germany, 27–30 June 2004;19 Suppl 1:i103.
Beckers 2002 {published data only}
    1. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum R, Bustion S, et al. Comparison of the non supplemented luteal phase characteristics after recombinant luteinizing hormone (r) HCG, rLH or GnRH agonist for oocyte maturation in IVF. Abstracts of the 18th annual meeting of the ESHRE. 2002; Vol. 17, issue 7:55.
Bennett 1997 {published data only}
    1. Bennett RA, Vidali A, Walker J, Navot D. Triggering ovulation with GnRH agonist to avoid ovarian hyperstimulation, frequently results in profound corpus luteum insufficiency. Fertility and Sterility 1997;68 Suppl 1:174‐5.
Bodri 2009 {published data only}
    1. Bodri D, Guillen JJ, Galind A, Mataro D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin‐releasing hormone agonist in gonadotropin‐releasing hormone antagonist‐treated oocyte donor cycles: findings of a large retrospective cohort study. Fertility and Sterility 2009;91(2):365‐71. [DOI: 10.1016/j.fertnstert.2007.11.049] - DOI - PubMed
Bodri 2010 {published data only}
    1. Bodri D, Guillén JJ, Trullenque M, Schwenn K, Esteve C, Coll O. Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing‐hormone agonist triggering in high‐risk oocyte donor cycles: a prospective, luteal‐phase follow‐up study. Fertil Steril. 2010;93(7):2418‐20. - PubMed
Bodri 2013 {published data only}
    1. Bodri D. Low‐dose hCG supplementation after GnRH agonist triggering: don't be too quick on the trigger.. Hum Reprod 2013;28(9):2315‐7. - PubMed
Bracero 2001 {published data only}
    1. Bracero NJ, Jurema MW, Posada MN, Whelan JG, Garcia JE, Vlahos NP. Triggering ovulation with leuprolide acetate (LA) instead of human chorionic gonadotropin (hCG) after the use of ganirelix for in vitro fertilization‐embryo transfer (IVF‐ET) does not compromise cycle outcome and may prevent ovarian hyperstimulation syndrome. Fertility and Sterility 2001;76 Suppl 3:93.
Bukulmez 2005 {published data only}
    1. Bukulmez O, Rehman KS, Langley M, Carr BR, Doody KM, Doody KJ. Triggering ovulation by GnRH agonist leuprolide acetate does not adversely affect the number and quality of the oocytes as compared to recombinant hCG in oocyte donation cycles. Abstract of the annual meeting of ASRM 2005;84 Suppl(1):314‐5.
Carone 2005 {published and unpublished data}
    1. Carone D, Vizziello GM, Schonauer LM, D’Amato G. Safety and efficacy of GnRH agonist to trigger ovulation in controlled ovarian hyperstimulation for ART with recombinant FSH and GnRH‐antagonist in high responders (PCOD) patients. Abstracts of the 8th International Symposium on GnRH‐analogues in Cancer and Human Reproduction.Salzburg, Austria 2005:A24.
Castillo 2007 {published data only}
    1. Castillo JC, Dolz M, Evangelio B, Abad de Velasco L, Bonilla‐Musoles F. Efficacy and security of luteal phase support with low doses of HCG in OHSS high risk patients triggered with GnRH agonists. Abstracts of the 23rd Annual Meeting of the ESHRE, Lyon, France, 1–4 July 2007;22(1):i 81.
Cerrillo 2011 {published data only}
    1. Cerrillo M, Pacheco A, Rodríguez S, Mayoral M, Ruiz M, García Velasco JA. Differential regulation of VEGF, cadherin, and angiopoietin 2 by trigger oocyte maturation with GnRHa vs hCG in donors: try to explain the lower OHSS incidence. Abstracts of the 25th annual meeting of the ESHRE, Amsterdam, June 28‐1 July, 2009;24(1):i60.
Check 1993 {published data only}
    1. Check J, Nazari A, Barnea E, Weiss W, Vetter B. The efficacy of short‐term gonadotrophin‐releasing hormone agonists versus human chorionic gonadotrophin to enable oocyte release in gonadotrophin stimulated cycles. Human Reproduction 1993; Vol. 8:568‐71. - PubMed
Chen 1998 {published data only}
    1. Chen SL, Dong H, Xing FQ. Clinical study of buserelin, instead of hCG, used for triggering follicular maturation in infertile patients with PCOS. Fertility and Sterility 1998; Vol. 70, issue 3:S396.
Chen 2012 {published data only}
    1. Chen SL, Ye DS, Chen X, Yang XH, Zheng HY, Tang Y, et al. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol. Human Reproduction 2012;27(5):1351‐6. - PubMed
Cunha 2002 {published data only}
    1. Cunha Filho J, Gratao A, Souza C, Freitas F, Vettori D, Passos E. Prospective randomized clinical trial to evaluate embryo quality (score) after GnRH agonist or HCG administration to induce oocyte maturation. Human Reproduction 2002; Vol. 17, issue 1:150, Abstract no: P‐440.
Daneshmand 2006 {published data only}
    1. Daneshmand ST, Shapiro BS, Garner FC, Aguirre M, Ross R. Cumulative pregnancy rates when using GnRH agonists instead of HCG for final oocyte maturation. Abstract of the annual meeting of ASRM 2006;86 Suppl(2):184‐5.
De Jong 2001 {published data only}
    1. Jong D, Hooren EG, Macklon NS, Mannaerts BM, Fauser B. Pregnancy and birth after GnRH agonist treatment for induction of final oocyte maturation in a woman undergoing ovarian stimulation for ICSI, using a GnRH antagonist (Orgalutran/Antagon) to prevent a premature LH surge: a case report. Journal of Assisted Reproduction and Genetics 2001;18:30‐3. - PMC - PubMed
Diaz 2003 {published data only}
    1. Diaz I, Guillen A, Pacheco A, Requena A, Simon C, Garcia Velasco J. Final oocyte maturation with GnRH‐agonist versus hCG in intrauterine insemination. Abstracts of the 19th annual meeting of the ESHRE.Madrid, Spain, June 29–July 2 2003;18(1):134.
DiLuigi 2010 {published data only}
    1. DiLuigi AJ, Engmann L, Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Gonadotropin‐releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high‐risk patients and leads to improved clinical outcomes compared with coasting. Fertility and Sterility 2010;94(3):1111‐4. - PubMed
Egbase 2002 {published data only}
    1. Egbase PE, Grudzinskas JG, Al Sharhan M, Ashkenani L. HCG or GnRH agonist to trigger ovulation in GnRH antagonist‐treated intrauterine insemination cycles: a prospective randomized study. Abstracts of the 18th Annual Meeting of the ESHRE, Vienna, Austria 2002 2002;17(1):2.
Eldar‐Geva 2007 {published data only}
    1. Eldar‐Geva T, Zylber‐Haran E, Babayof R, Halevy‐Shalem T, Ben‐Chetrit A, Tsafrir A, et al. Similar outcome for cryopreserved embryo transfer following GnRH antagonist/GnRH agonist, GnRH ‐antagonist/HCG or long protocol ovarian stimulation. Reproductive BioMedicine Online 2007;14(2):148‐54. - PubMed
Emperaire 1992 {published data only}
    1. Emperaire JC, Ruffie A, Audebert AJ. [Ovulation induction by endogenous LH released by the administration of an LHRH agonist after follicular stimulation for in vitro fertilization]. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction 1992; Vol. 21:489‐94. - PubMed
Engmann 2005 {published data only}
    1. Engmann LA, Diluigi D, Schmidt J, Nulsen D, Maier C, Benadiva. Prevention of ovarian hyperstimulation syndrome (OHSS) with the use of gonadotropin releasing hormone (GnRH) agonist to trigger final oocyte maturation after cotreatment with GnRH antagonist in patients with polycystic ovarian syndrome (PCOS) or previous high response undergoing IVF treatment. A prospective randomized clinical trial. Abstract of the annual meeting of ASRM 2005;84 Suppl(1):96.
Engmann 2006 {published data only}
    1. Engmann L, Siano L, Weitzman V, Nulsen J, Maier D, Benadiva C. Induction of oocyte maturation with GnRH agonists in high‐risk patients undergoing IVF treatment does not adversely affect implantation rate. Fertility and Sterility 2006;86(1):797‐8.
Engmann 2006a {published data only}
    1. Engmann L, Siano L, Schmidt D, Nulsen J, Maier D, Benadiva C. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reproductive BioMedicine Online 2006; Vol. 13, issue 5:639‐44. - PubMed
Engmann 2011 {published data only}
    1. Engmann L, Romak J, Nulsen J, Benadiva C, Peluso C. In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin‐releasing hormone agonist trigger of oocyte maturation. Fertility and Sterility 2011;96(1):198‐202. - PubMed
Engmann 2012 {published data only}
    1. Engmann L, Benadiva C. Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support. Fertility and Sterility 2012;97(3):531‐3. - PubMed
Erb 2009 {unpublished data only}
    1. Erb TM, Vitek W, Wakim AN. Gonadotropin‐releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program. Fertility and Sterility 2010; Vol. 93, issue 2:374‐8. - PubMed
Fatemi 2013 {published data only}
    1. Fatemi HM, Polyzos NP, Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, et al. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle‐stimulating hormone‐gonadotropin‐releasing hormone antagonist in vitro fertilization cycles. Fertility and Sterility 2013;100(3):742‐7. - PubMed
Galera 2005 {published data only}
    1. Galera F, Rayward J, Verdu V, Villafanez V, Manzanares MA, Garijo E. GnRH agonist triggered LH surge: P4, E2 levels. IVF outcome. Abstracts of the 21st Annual meeting of the ESHRE , Copenhagen, Denmark, 19‐22, 2005;20(1):i 109.
Garcia‐Velasco 2010 {published data only}
    1. Garcia‐Velasco JA, Motta L, López A, Mayoral M, Cerrillo M, Pacheco A. Low‐dose human chorionic gonadotropin versus estradiol/progesterone luteal phase support in gonadotropin‐releasing hormone agonist‐triggered assisted reproductive technique cycles: understanding a new approach. Fertility and Sterility 2010;94(7):2820‐3. - PubMed
Garcia‐Velasco 2012 {published data only}
    1. Garcia‐Velasco JA. Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. Fertility and Sterility 2012;97(3):527‐8. - PubMed
Goto 2003 {published data only}
    1. Goto T, Oka C, Tatsuhiro T, Mukaida T, Takahashi K. Single dose nasal spray of gonadotropin releasing hormone (GnRH) agonist effectively matures oocytes for in vitro fertilization in an ovarian stimulation protocol using clomiphene citrate, gonadotropin, and GnRH antagonist. Abstracts of the Annual Meeting of the ASRM 2003;80 Suppl(3):6.
Griesinger 2005 {published data only}
    1. Griesinger G, Schultze‐Mosgau A, Schroer A, Steirteghem A, Devroey P, Diedrich K, et al. GnRH‐agonist instead of hCG for final oocyte maturation in GnRH‐antagonist cycles. 21st Annual Meeting of the European Society of Human Reproduction and Embryology, Copenhagen, Denmark, 19‐22 June 2005 2005:i91.
Griesinger 2007a {published data only}
    1. Griesinger G, Kolibianakis EM, Papanikolaou EG, Diedrich K, Steirteghem A, Devroey PC. Triggering of final oocyte maturation with gonadotropin‐releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen‐thawed embryo replacement cycles. Fertility and Sterility 2007;88(3):616‐21. [DOI: 10.1016/j.fertnstert.2006.12.006] - DOI - PubMed
Griesinger 2007b {published data only}
    1. Griesinger G, Otte S, Schroer A, Ludwig AK, Diedrich K, Al‐Hasani S, et al. Elective cryopreservation of all pro nuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof‐of‐concept study. Human Reproduction 2007;22(5):1348–52. [DOI: 10.1093/humrep/dem006] - PubMed
Griesinger 2010 {published data only}
    1. Griesinger G, Berndt H, Schultz L, Depenbusch M, Schultze‐Mosgau A. Cumulative live birth rates after GnRH‐agonist triggering of final oocyte maturation in patients at risk of OHSS: a prospective, clinical cohort study. European Journal of Obstetric and Gynecologic Reproduction Biology 2010;149(2):190‐4. - PubMed
Griesinger 2011 {published data only}
    1. Griesinger G1, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S. Ovarian hyperstimulation syndrome prevention by gonadotropin‐releasing hormone agonist triggering of final oocyte maturation in a gonadotropin‐releasing hormone antagonist protocol in combination with a "freeze‐all" strategy: a prospective multicentric study. Fertility and Sterility 2011;95(6):2029‐33. - PubMed
Griffin 2012 {published data only}
    1. Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L. Dual trigger of oocyte maturation with gonadotropin‐releasing hormone agonist and low‐dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertility and Sterility 2012;97(6):1316‐20. - PubMed
Herrero 2010 {published data only}
    1. Herrero L, Pareja S, Losada C, et al. Avoiding the use of human chorionic gonadotropin combined with oocyte vitrification and GnRH agonist triggering versus coasting: a new strategy to avoid ovarian hyperstimulation syndrome. Fertility and Sterility 2010;95(3):1137‐40. - PubMed
Humaidan 2011 {published data only}
    1. Humaidan P, Westergaard LG, Mikkelsen AL, Fukuda M, Yding Andersen C. Levels of the epidermal growth factor‐like peptide amphiregulin in follicular fluid reflect the mode of triggering ovulation: a comparison between gonadotrophin‐releasing hormone agonist and urinary human chorionic gonadotrophin. Fertility and Sterility 2011; Vol. 95, issue 6:2034‐8. - PubMed
Humaidan 2012 {published data only}
    1. Humaidan P, Vaerenbergh I, Bourgain C, Alsbjerg B, Blockeel C, Schuit F, et al. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co‐treated IVF cycles. Human Reproduction 2012; Vol. 27, issue 11:3259‐72. - PubMed
Imbar 2012 {published data only}
    1. Imbar T, Kol S, Lossos F, Bdolah Y, Hurwitz A, Haimov‐Kochman R. Reproductive outcome of fresh or frozen‐thawed embryo transfer is similar in high‐risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support. Human Reproduction 2012;27(3):753‐9. - PubMed
Itskovitz‐Eldor 2000 {published data only}
    1. Itskovitz‐Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report. Human Reproduction 2000;15(9):1965‐8. - PubMed
Johnston‐MacAnanny 2007 {published data only}
    1. Johnston‐MacAnanny EB, DiLuigi AJ, Benadiva CA, Maier DB, Nulsen JC, Engmann LL. Choice of medication for oocyte maturation for in vitro fertilization (IVF) gonadotropin releasing hormone (GnRH) antagonist cycles; Human chorionic gonadotropin (HCG) vs leuprolide acetate (LA). Abstract of the annual meeting of ASRM 2007;88 Suppl(1):142.
Joo 2012 {published data only}
    1. Joo JK, Choi JR, Son JB, Ko GR, Lee KS. Preliminary clinical outcome of novel strategy for the maximization of cumulative pregnancy rates per retrieval in normal responders. Clinical and Experimental Reproductive Medicine 2012;39(1):33‐9. - PMC - PubMed
Kaur 2012 {published data only}
    1. Kaur H, Krishna D, Shetty N, Krishnan S, Srinivas MS, Rao KA. Effect of pre‐ovulatory single dose GnRH agonist therapy on IVF outcome in GnRH antagonist; a prospective study. Journal of Reproduction and Infertility 2012;13(4):225‐31. - PMC - PubMed
Kol 2012 {published data only}
    1. Kol S, Homburg R, Alsbjerg B, Humaidan P. The gonadotropin‐releasing hormone antagonist protocol—the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation. Acta Obstetricia et Gynecologica Scandinavica 2012;91(6):643‐7. - PubMed
Krause 2006 {published data only}
    1. Krause BT, Ohlinger O. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2006;126:87–92. - PubMed
Kummer 2013 {published data only}
    1. Kummer NE, Feinn RS, Griffin DW, Nulsen JC, Benadiva CA, Engmann LL. Predicting successful induction of oocyte maturation after gonadotropin‐releasing hormone agonist (GnRHa) trigger. Human Reproduction 2013;28(1):152‐9. - PubMed
LaMonica2007 {published data only}
    1. LaMonica R, Siano LJ, Nulsen JC, Maier DB, Benadiva CA, Engmann LL. Elective cryopreservation of all embryos after GnRH agonist trigger is not justified because of the comparable success rates between fresh and cryo‐thawed embryo transfers. Abstracts of the annual meeting of ASRM 2007;88 Suppl(1):135.
Lanzone 1994 {published data only}
    1. Lanzone A, Fulghesu AM, Villa P, Guida C, Guido M, Nicoletti MC, et al. Gonadotropin‐releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles. Fertility and Sterility 1994;62(1):35‐41. - PubMed
Lanzone 1994a {published data only}
    1. Lanzone A, Fulghesu AM, Villa P, Guida C, Guido M, Nicoletti MC, et al. Gonadotropin‐releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles [erratum appears in Fertil Steril 1995 Mar 63(3):684‐5]. Fertility and Sterility 1994; Vol. 62, issue 1:35‐41. - PubMed
Lewit 1996 {published data only}
    1. Lewit N, Kol S, Manor D, Itskovitz‐Eldor J. Comparison of gonadotrophin‐releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome. Human Reproduction 1996;11(7):1399‐402. - PubMed
Lin 2013 {published data only}
    1. Lin YH, Huang MZ, Hwang JL, Chen HJ, Hsieh BC, Huang LW, et al. Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels—a retrospective study. Journal of Assisted Reproduction and Genetics 2013;30(6):753‐9. - PMC - PubMed
Lin MH 2013 {published data only}
    1. Lin MH, Shao‐Ying Wu F, Kuo‐Kuang lee R, Li SH, Lin SY, Hwu YM. Dual trigger with combination of gonadotropin‐releasing hormone agonist and human chorionic gonadotropin significantly improves the live‐birth rate for normal responders in GnRH‐antagonist cycles. Fertilty and Sterility 2013;100(5):1296‐302. - PubMed
lliodromiti 2013 {published data only}
    1. Iliodromiti S, Blockeel C, Tremellen KP, Fleming R, Tournaye H, Humaidan P, et al. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high‐risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Human Reproduction 2013;28(9):2529‐36. - PubMed
Loumaye 2004 {published data only}
    1. Loumaye E, Pirard C, Donnez J. GnRH agonist as a novel luteal support: results of a pilot study. Abstracts of the 20th Annual Meeting of the ESHRE, Berlin, Germany, 27 ‐ 30 June 2004;19(1):i4.
Loumaye 2007 {published data only}
    1. Loumaye E, Pirard C, Donnez J. Efficacy of GnRH agonist as luteal support: results of a prospective, randomized, comparative study. Abstracts of the 23rd Annual Meeting of the ESHRE, Lyon,France 1‐4 July 2007;22(1):i82.
Melo 2007 {published data only}
    1. Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor‐blind study [Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, et al. A randomized, prospective, controlled, assessor‐blind study, comparing triptorelin vs rhCG as trigger oocyte maturation in oocyte donors]. 2007 Fertility and Sterility; Vol. 88, issue 1:34.
Meltzer 2002 {published data only}
    1. Meltzer S, Girsh E, Shults A, Katz N, Zohav E, Tur‐Kaspa I. Prevention of ovarian hyperstimulation syndrome in high responders undergoing IVF treatment with GnRH antagonist combined with single dose of GnRH agonist, instead of HCG, for the induction of oocyte maturation. Abstracts of the 18th Annual Meeting of the ESHRE 2002;17 Suppl1:89.
Nelson 2013 {published data only}
    1. Nelson SM. Venous thrombosis during assisted reproduction: novel risk reduction strategies. Thrombosis Research 2013;Suppl 1:S1‐S3. - PubMed
Nevo 2003 {published data only}
    1. Nevo O, Eldar‐Geva T, Kol BS, Itskovitz‐Eldor J. Lower levels of inhibin A and pro‐C during the luteal phase after triggering oocyte maturation with a gonadotropin releasing hormone agonist versus human chorionic gonadotropin. Fertility and Sterility 2003;79(5):1123‐8. [DOI: ] - PubMed
Olivennes 2001 {published data only}
    1. Olivennes F. Induction of final oocyte maturation by a single dose of GNRH agonist after ganirelix treatment. Gynecological Endocrinology 2001;15(Suppl 2):7.
Orvieto 2006 {published data only}
    1. Orvieto R, Zagatsky I, Yullzari‐Roll V, Marca A, Fisch B. Substituting human gonadotropin by gonadotropin‐releasing hormone to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation. Gynecological Endocrinology 2006;22(8):437‐40. - PubMed
Orvieto 2013 {published data only}
    1. Orvieto R, Nahum R, Zohav E, Liberty G, Anteby EY, Meltcer S. GnRH‐agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH‐agonist combined with multidose GnRH‐antagonist protocol. Gynecological Endocrinology 2013;29(1):51‐3. - PubMed
Parneix 2001 {published data only}
    1. Parneix I, Emperaire JC, Ruffie A, Parneix P. Triggering of ovulation using different regimens of gonadotropin‐releasing hormone agonist or human chorionic gonadotropin. Gynecologie, Obstetrique & Fertilite 2001; Vol. 29, issue 2:100‐5. - PubMed
Peñarrubia 1998 {published data only}
    1. Peñarrubia J, Balasch J, Fábregues F, Creus M, Casamitjana R, Ballescá JL, et al. Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin‐releasing hormone agonist‐induced ovulations in gonadotrophin‐stimulated cycles. Human Reproduction 1998;13(12):3315‐8. - PubMed
Ricciarelli 2006 {published data only}
    1. Ricciarelli E, Acevedo‐Martin B, Gomez‐Palomares JL, Pareja A, Hernandes ER. Triggering ovulation with GnRH agonists does not compromise embryo implantability. Human Reproduction 2006; Vol. 21, issue Suppl:i35.
Schachter 2007 {published data only}
    1. Schachter M, Friedler S, Ron‐El R, Zimmerman AL, Strassburger D, Bern O, et al. Can pregnancy rate be improved in gonadotropin ‐releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study. Fertility and Sterility 2008;90(4):1087‐93. [DOI: 10.1016/j.fertnstert.2007.07.1316] - DOI - PubMed
Schmidt 1995 {published data only}
    1. Schmidt Sarosi C, Kaplan DR, Sarosi P, Essig MN, Licciardi FL, Keltz M, et al. Ovulation triggering in clomiphene citrate stimulating cycles: human chronic gonadotropin versus a gonadotropin releasing hormone agonist. Journal of Assisted Reproduction & Genetics 1995; Vol. 12, issue 3:167‐73. - PubMed
Schmidt‐Sarosi 1995 {published data only}
    1. Schmidt‐Sarosi C, Kaplan DR, Sarosi P, Essig MN, Licciardi FL, Keltz M, et al. Ovulation triggering in clomiphene citrate‐stimulated cycles: human chorionic gonadotropin versus a gonadotropin releasing hormone agonist. Journal of Assisted Reproduction and Genetics 1995;12(3):167‐74. - PubMed
Seyhan 2013 {published data only}
    1. Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Human Reproduction 2013;28(9):2522‐8. - PubMed
Shalev 1995 {published data only}
    1. Shalev E, Geslevich Y, Matilsky M, Ben Ami M. Gonadotrophin‐releasing hormone agonist compared with human chorionic gonadotrophin for ovulation induction after clomiphene citrate treatment. Human Reproduction 1995; Vol. 10:2541‐4. - PubMed
Shanis 1995 {published data only}
    1. Shanis BS, Check JH. Efficacy of gonadotropin‐releasing hormone agonists to induce ovulation following low‐dose human menopausal gonadotropin stimulation. Recent Progress in Hormone Research 1995:483‐6. - PubMed
Shapiro 2007 {published data only}
    1. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Ross R. Comparison of human chorionic gonadotropin and gonadotropin‐releasing hormone agonist for final oocyte maturation in oocyte donor cycles. Fertility and Sterility 2007;88(1):237. [DOI: 10.1016/j.fertnstert.2006.11.069] - DOI - PubMed
Shapiro 2008 {published data only}
    1. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Ross R. Gonadotropin‐releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertility and Sterility 2008;90(1):231‐3. - PubMed
Shapiro 2011 {published data only}
    1. Shapiro BS, Daneshmand ST, Garner FC, et al. Comparison of "triggers" using leuprolide acetate alone or in combination with low‐dose human chorionic gonadotropin. Fertility and Sterility 2011;95(8):2715‐7. - PubMed
Shapiro 2011a {published data only}
    1. Shapiro BS, Daneshmand ST, Restrepo H, Garner FC, Aguirre M, Hudson C. Efficacy of induced luteinizing hormone surge after "trigger" with gonadotropn‐releasing hormone agonist. Fertility and Sterility 2011;95(2):826‐8. - PubMed
Sismangoul 2009 {published data only}
    1. Sismanoglu A1, Tekin HI, Erden HF, Ciray NH, Ulug U, Bahceci M. Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross‐over trial. Journal of Assisted Reproduction and Genetics 2009;26(5):251‐6. - PMC - PubMed
Toner 2006 {published data only}
    1. Toner JP, Denis AL, Hasty LA, Carpenter S, Bates W. Lupron trigger experience in GnRH antagonist ART cycles. Abstracts of the Annual meeting of the ASRM 2006;86(3):S118‐9.
Westergaard 2004 {published data only}
    1. Westergaard L, Andersen CY, Humaidan P, Bredkjær HE, Bungum L, Bungum M, et al. Significant reduction of clinical pregnancy and implantation rates by use of GnRH agonist (Buserelin) as compared to hCG to induce ovulation in FSH/GnRH antagonist treated IVF/ICSI cycles. Abstracts of the 20th Annual Meeting of the ESHRE,Berlin,Lyon, 27‐30 June 2004;19(1):i3.
Wilkinson 2007 {published data only}
    1. Wilkinson SC, Walker SA, Hayes BA, Donesky BW, Bird JS, Anderson AR. Gonadotropin releasing hormone (GnRH) agonist trigger following antagonist protocols in anonymous oocyte donors minimizes ovarian hyperstimulation syndrome. Abstract of the annual meeting of ASRM 2007;88(1):S131.
Yding 1993 {published data only}
    1. Yding Andersen C, Westergaard LG, Figenschau Y, Bertheussen K, Forsdahl F. Endocrine composition of follicular fluid comparing human chorionic gonadotrophin to a gonadotrophin‐releasing hormone agonist for ovulation induction. Human Reproduction 1993; Vol. 8, issue 6:840‐3. - PubMed

Additional references

Delvigne 2003
    1. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome. Human Reproduction Update 2003;9:77‐96. - PubMed
Emperaire 2004
    1. Emperaire JC, Parneix I, Ruffie A. Luteal phase defects following agonist‐triggered ovulation: a patient‐dependent response. Reproductive Biomedicine Online 2004;9:22‐7. - PubMed
Felberbaum 1995
    1. Felberbaum PE, Reissmannb T, Kiipkera W, Bauera O, Al Hasania S, Diedrich C, et al. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (cetrorelix) in women with tubal infertility. European Journal of Obstetrics, Gynecology, and Reproductive Biology 1995;61:151‐5. - PubMed
Forman 1998
    1. Forman R, Fries N, Tastart J, Belaisch J, Hazout A, Frydman R. Evidence of an adverse effect of elevated serum estradiol concentrations on embryo implantation. Fertility and Sterility 1998;49:118‐22. - PubMed
Golan 1989
    1. Golan A, Ron‐el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstetrical & Gynecological Survey 1989;44(6):430‐40. - PubMed
Gonen 1990
    1. Gonen Y, Balakier H, Powell W, Casper RF. Use of GnRH agonist to trigger follicular maturation for in vitro fertilization. The Journal of Clinical Endocrinology and Metabolism 1990;71:918–23. - PubMed
Griesinger 2006
    1. Griesinger G, Diedrich K, Dovroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta‐analysis. Human Reproduction Update 2006;12(2):159‐68. [DOI: ] - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011:www.cochrane‐handbook.org.
Humaidan 2009
    1. Humaidan P, Papanikolaou EG, Tarlatzis BC. GnRHa to trigger final oocyte maturation: a time to reconsider. Human Reproduction 2009;24(10):2389‐94. - PubMed
Kol 2004
    1. Kol S. Luteolysis induced by a gonadotropin‐releasing hormone agonists the key to prevention of ovarian hyperstimulation syndrome. Fertility and Sterility 2004;81(1):1–5. - PubMed
Kol 2008
    1. Kol S. GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?. Journal of Assisted Reproduction and Genetics 2008;25:63‐6. [DOI: 10.1007/s10815-008-9198-1] - DOI - PMC - PubMed
Kol 2013
    1. Kol S, Humaidan P. GnRH agonist triggering: recent developments. Reproductive Biomedicine Online 2013;26(3):226‐30. - PubMed
Lundh 2012
    1. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012;2012 Dec 12;12:MR000033:doi: 10.1002/14651858.MR000033.pub2. Review.. - PubMed
Navot 1992
    1. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility 1992;58:249‐61. - PubMed
Olivennes 1996
    1. Olivennes F, Fanchin R, Bouchard P, Taieb J, Frydman R. Triggering of ovulation by a gonadotropin‐releasing hormone (GnRH) agonist in patients pretreated with GnRH antagonist. Fertility and Sterility 1996;66:151‐3. - PubMed
Simon 1995
    1. Simon C, Cano F, Valbuena D, Remohi J, Pellicer A. Clinical evidence for a detrimental effect on uterine receptivity of high serum estradiol concentrations in high and normal responders. Human Reproduction 1995;10:2432‐7. - PubMed
Simon 1998
    1. Simon C, Garcia Velasco JJ, Valbuena D, Peinado JA, Moreno C, Rehmohi J, et al. Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle‐stimulating hormone step‐down regimen. Fertility and Sterility 1998;70:234‐9. - PubMed
Tavaniotou 2002
    1. Tavaniotou A, Albano C, Smitz J, Devroey P. Impact of ovarian stimulation on corpus luteum function and embryonic implantation. Journal of Reproductive Immunology 2002;55:123‐30. - PubMed
Tay 2002
    1. Tay CC. Use of gonadotropin‐releasing hormone agonist to trigger ovulation. Human Fertility 2002;5:G35‐7. - PubMed
Valbuena 2001
    1. Valbuena D, Martin J, Palbo JL, Remohi J, Pellicer A, Simon C. Increasing levels of estradiol are deleterious to embryonic implantation because they directly affect the embryo. Fertility and Sterility 2001;76:962‐8. - PubMed

References to other published versions of this review

Youssef 2010
    1. Youssef MA, Veen F, Al‐Inany HG, Griesinger G, Mochtar MH, Wely M. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev 2010;11(CD008046):doi: 10.1002/14651858.CD008046.pub2.. - PubMed

Publication types

MeSH terms

Substances